CH14.18 1021 Antibody and IL2 After Haplo SCT in Children With Relapsed Neuroblastoma
Condition(s):Neuroblastoma RecurrentLast Updated:December 8, 2023Completed
Hide Studies Not Open or Pending
Condition(s):Neuroblastoma RecurrentLast Updated:December 8, 2023Completed
Condition(s):NeuroblastomaLast Updated:October 22, 2020Completed
Condition(s):NeuroblastomaLast Updated:October 4, 2021Active, not recruiting
Condition(s):NeuroblastomaLast Updated:July 14, 2020Unknown status
Condition(s):High Risk NeuroblastomaLast Updated:August 17, 2021Completed
Condition(s):NeuroblastomaLast Updated:September 23, 2015Completed
Condition(s):Disseminated Neuroblastoma; Recurrent Neuroblastoma; Regional NeuroblastomaLast Updated:January 16, 2013Completed
Condition(s):NeuroblastomaLast Updated:August 2, 2023Recruiting
Condition(s):Localized Resectable Neuroblastoma; Localized Unresectable Neuroblastoma; Neurotoxicity Syndrome; Pain; Regional Neuroblastoma; Stage 4 Neuroblastoma; Stage 4S NeuroblastomaLast Updated:October 1, 2019Completed
Condition(s):Metastatic Malignant Neoplasm in the Lung; Metastatic Osteosarcoma; Recurrent OsteosarcomaLast Updated:October 26, 2023Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.